Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder

Home > Science Hub > Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
Back to the list

July 18, 2022

Bernadett S et al. European Urology, 2022

Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder

Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder

Download Publication

You might also be interested by

Videos

Poster Video: Induction of an effective immune response is an essential element of cancer immunotherapy

September 2, 2025

Histopathology

More info

Posters

Development of a Pathologist Scoring Method to Determine Inflamed, Excluded or Desert Immune Phenotype in Carcinoma

March 5, 2025

Histopathology

More info

Scientific Publications

Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer

January 27, 2025

Histopathology

More info

Posters

Development of a visual scoring method to determine inflamed, excluded or desert immune phenotype in Non-Small Cell Lung Cancer, Colorectal Cancer, and Urothelial Cancer

November 7, 2024

Histopathology

More info